Monogram Acquisition Bolsters LabCorp's PGx Test Portfolio, Companion Dx Know-how

LabCorp's $107 million offer to acquire Monogram gives it access to molecular diagnostics and pharmacogenomic tests that are clinically validated and are free of regulatory challenges. Although Monogram wasn't looking to be acquired, the deal would allow broader marketing of its tests by using LabCorp's national infrastructure.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.